UniQure Submits Huntington’s Gene Therapy for UK Approval Amid US Uncertainty

UniQure plans to seek approval in the United Kingdom for its Huntington’s disease gene therapy, marking the first submission for this closely watched treatment. This decision occurs amidst uncertainty surrounding the therapy’s future in the United States.

The submission to the UK regulatory authorities represents a significant step for UniQure, as it aims to bring its gene therapy to market. The company is moving forward with its plans in the UK while navigating a complex regulatory landscape in the U.S., where the treatment’s path to approval remains unclear.
n

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 30, 2026

Author

GOAI